Drugs / SIPI6398
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07626034 | Aug 2026 → Oct 2027 expected | schizophrenia | Shanghai Zhongze Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-06 | Shanghai Zhongze Therapeutics Co., Ltd. | Results 中泽医药宣布成功完成ZZ6398在健康志愿者中的首次单剂量爬坡试验 zhongzetherapeutics.com ↗
I期临床试验结果显示 ZZ6398 在健康志愿者中安全且耐受性良好，PK 数据优于预期，对此我们感到非常兴奋。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-06 | Shanghai Zhongze Therapeutics Co., Ltd. | 中泽医药宣布成功完成ZZ6398在健康志愿者中的首次单剂量爬坡试验 zhongzetherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIPI6398 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07626034 ↗ |
| Route | Oral | “administered orally” NCT07626034 ↗ |